VVUS VIVUS Inc.

1.24
-0.07  -5%
Previous Close 1.31
Open 1.33
Price To Book -0.32
Market Cap 22,155,944
Shares 17,867,697
Volume 1,066,537
Short Ratio
Av. Daily Volume 2,390,248
Stock charts supplied by TradingView

NewsSee all news

  1. VIVUS Announces Closing of $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

    CAMPBELL, Calif., April 03, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS, the "Company")), a biopharmaceutical company, today announced the completion of its previously announced registered direct offering of

  2. VitalTech Partners with VIVUS Pharmaceuticals to Accelerate Launch of Telehealth and Remote Patient Monitoring Modules

    PLANO, Texas, April 3, 2020 /PRNewswire/ -- VitalTech, a rapidly growing market leader in Virtual Care, announced today its partnership with VIVUS, Inc, a publicly held biopharmaceutical company (NASDAQ:VVUS). Leveraging

  3. VIVUS Announces $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

    CAMPBELL, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS, the "Company")), a biopharmaceutical company, today announced that it has entered into definitive agreements with several institutional and

  4. VIVUS Accelerates the Launch of Telemedicine and Remote Monitoring Modules to Facilitate Effective Patient Care During "Social Distancing"

    Virtual office visits and smart health devices available through the VIVUS Health Platform give physicians new tools for optimizing patient care and protecting the health of those at increased risk for COVID-19

  5. VIVUS Reports Fourth Quarter and Full Year 2019 Financial Results

    - Company to host conference call today at 4:30pm ET - CAMPBELL, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a biopharmaceutical company, today reported financial results for

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved July 17, 2012.
Qnexa
Obesity
Approved Apr 27 2012. sNDA label change also approved 17 Sept 2014
Avanafil
Erectile dysfunction
Phase 1 trial completed July 2018.
VI-0106
Pulmonary arterial hypertension (PAH)

Latest News

  1. VIVUS Announces Closing of $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

    CAMPBELL, Calif., April 03, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS, the "Company")), a biopharmaceutical company, today announced the completion of its previously announced registered direct offering of

  2. VitalTech Partners with VIVUS Pharmaceuticals to Accelerate Launch of Telehealth and Remote Patient Monitoring Modules

    PLANO, Texas, April 3, 2020 /PRNewswire/ -- VitalTech, a rapidly growing market leader in Virtual Care, announced today its partnership with VIVUS, Inc, a publicly held biopharmaceutical company (NASDAQ:VVUS). Leveraging

  3. VIVUS Announces $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

    CAMPBELL, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS, the "Company")), a biopharmaceutical company, today announced that it has entered into definitive agreements with several institutional and

  4. VIVUS Accelerates the Launch of Telemedicine and Remote Monitoring Modules to Facilitate Effective Patient Care During "Social Distancing"

    Virtual office visits and smart health devices available through the VIVUS Health Platform give physicians new tools for optimizing patient care and protecting the health of those at increased risk for COVID-19

  5. VIVUS Reports Fourth Quarter and Full Year 2019 Financial Results

    - Company to host conference call today at 4:30pm ET - CAMPBELL, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a biopharmaceutical company, today reported financial results for

  6. VIVUS Completes Enrollment in Phase 4 Safety and Efficacy Study of Qsymia® in Adolescents

    -Post-marketing study designed to evaluate Qsymia as an approach to weight management in a growing patient population with significant unmet medical need- CAMPBELL, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- VIVUS,

  7. VIVUS Announces Commercial Launch of Qsymia® in the Republic of Korea Establishing New Royalty Revenue Stream

    - VIVUS to Receive Milestone Payment from Alvogen; Significant Worldwide Growth Potential for Qsymia - CAMPBELL, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a

  8. VIVUS to Host Fourth Quarter Business Update and Financial Results Conference Call on Tuesday, March 3, 2020

    CAMPBELL, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) today announced that it will report financial results and provide a business update for the fourth quarter of 2019 after the market close on

  9. VIVUS Receives U.S. Food and Drug Administration Approval for Improved Formulation of PANCREAZE® with a 36-Month Shelf Life

    CAMPBELL, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) ("VIVUS"), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New

  10. New Data Further Demonstrate Effectiveness of VIVUS' Qsymia as a Weight Management Tool

    -Data published in Journal of General Internal Medicine show that patients using Qsymia and other weight loss tools, lost at least 5% of body weight loss compared with those not using Qsymia- CAMPBELL, Calif., Jan. 07,

  11. VIVUS to Present at Biotech Showcase on January 13, 2020

    CAMPBELL, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer, will present at the Biotech Showcase™

  12. VIVUS Adopts Stockholder Rights Plan

    CAMPBELL, Calif., Dec. 31, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a biopharmaceutical company, today announced that on December 30, 2019 its board of directors adopted a new stockholder

  13. VIVUS Announces New Data Supporting the Safety and Efficacy of Qsymia® in Adolescents with Obesity

    -Data published in Diabetes, Obesity and Metabolism demonstrate that Qsymia provides statistically significant weight loss compared with placebo over an 8 week period, provide basis for ongoing 56 week phase 4 study in

  14. VIVUS to Present at Piper Jaffray 31st Annual Healthcare Conference on December 3, 2019

    CAMPBELL, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer at VIVUS, will present at the Piper

  15. New Clinical Data Demonstrate VIVUS' Qsymia® is Effective at Reducing Binge Eating in Patients with Binge-Eating Disorder or Bulimia Nervosa

    -Data published in International Journal of Eating Disorders show patients in the Qsymia group had 75% decrease in binge day frequency compared with 19% for placebo- CAMPBELL, Calif., Nov. 20, 2019 (GLOBE NEWSWIRE)

  16. VIVUS Reports Third Quarter 2019 Financial Results

    CAMPBELL, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on

  17. VIVUS Announces Departures of Eric W. Roberts and Allan L. Shaw from Board of Directors

    CAMPBELL, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a biopharmaceutical company, announced today that Eric W. Roberts and Allan L. Shaw have resigned from its Board of

  18. VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Tuesday, November 5, 2019

    CAMPBELL, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) today announced that it will report financial results and provide a business update for the third quarter of 2019 after the market close on

  19. VIVUS to Highlight Integrated Approach to More Effective Weight Management in Panel Discussion at the Cleveland Clinic 2019 Medical Innovation Summit

    CAMPBELL, Calif., Oct. 21, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a biopharmaceutical company, announced today that John Amos, Chief Executive Officer, will participate in a panel

  20. VIVUS Announces Acceptance of Qsymia Decentralized Marketing Authorization Application in Europe

    CAMPBELL, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a biopharmaceutical company, announced today that European regulatory agencies in Sweden, Denmark, Finland, Iceland,

  21. VIVUS Initiates Pay Down of Secured Debt and Announces Management Changes

    -Reduction of $48.6 million of Secured Debt will result in total interest savings of $10.5 million--Organizational change streamlines commercial operations- CAMPBELL, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) --

  22. VIVUS to Present at Upcoming Conferences

    CAMPBELL, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer at VIVUS, will present at the

  23. VIVUS to Share Qsymia® Safety and Efficacy Data with a Global Audience at ICOMES & AOCO 2019

    -Conference in Seoul provides opportunity to introduce an international audience to the clinical safety and benefits of Qsymia following its approval in the Republic of Korea- CAMPBELL, Calif., Aug. 27, 2019 (GLOBE